Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million

KRSA-028 is advancing toward clinical development, with Phase 1 healthy-volunteer data expected in mid-2027. Interim proof-of-concept data in Alzheimer's patients are anticipated by year-end 2027 or Q1 2028, providing a long-dated but potentially meaningful clinical catalyst.